Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform

Analysts at Leerink Swann initiated coverage on Pacira Pharmaceuticals Inc PCRX with a Market Perform rating. The target price for Pacira Pharmaceuticals is set to $86. Pacira Pharmaceuticals shares have dropped 11.28 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. Pacira Pharmaceuticals' shares rose 1.35 percent to close at $78.18 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsLeerink Swann
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!